Thomas Hensing

Clinical applications of proton MR spectroscopy in oncology.

The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel.

Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm).

Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.

Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer.

Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer.

A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer.

Clinical evaluation and staging of patients who have lung cancer.

Duration of therapy in advanced, metastatic non-small-cell lung cancer.

Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program.

Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer.

Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story.

Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer.

Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis.

Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition).

An innovative symptom monitoring tool for people with advanced lung cancer: a pilot demonstration.

Should health-related quality of life be measured in cancer symptom management clinical trials? Lessons learned using the functional assessment of cancer therapy.

Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer.

Prevalence of poor performance status in lung cancer patients: implications for research.

The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer.

Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.

Nanoscale cellular changes in field carcinogenesis detected by partial wave spectroscopy.

A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer.

Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening.

Nanocytology for field carcinogenesis detection: novel paradigm for lung cancer risk stratification.

Personalized treatment of lung cancer.

Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.

Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database.

A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer.

A brief symptom index for advanced lung cancer.

Effect of an electronic health record on the culture of an outpatient medical oncology practice in a four-hospital integrated health care system: 5-year experience.